WRAL Tech Wire

Argos Therapeutics raises $25M after withdrawing IPO

The Durham-based drug development firm lands a new investor as well as more backing from Intersouth and Aurora Funds. The deal follows Argos' recent decision to terminate plans to go public.

Argos process

Nanotech startup funding: What investors are looking for

Nanotech companies are clamoring for financing at a time when investor purse strings remains tight. Some investors are showing interest in nanotechnology investments, but that interest doesn't mean that they approach these deals with any less caution.

Nanotech conference

Argos Therapeutics aims for as much as $79M in IPO

The Durham based venture capital-backed firm estimated an IPO price of between $13 and $15 per share. Some 5.25 million shares will be offered.

Argos process

$40M Aldagen deal is no quick exit for its investors

Aldagen, who had tried twice to go public only to withdraw both times amid poor market conditions, gets a partner interested in developing its stem cell treatments. Cytomedix gains prospective regenerative medicine therapies for its pipeline. But a payoff remains in the future and depends on drug trial results.

Aldagen's pipeline

Durham stem cell firm Aldagen sold for up to $40M

Regenerative medicine company Cytomedix has acquired the venture-capital backed company in a $16 million stock deal plus millions more in stock options. Aldagen investors include Intersouth and Aurora Funds.

A purified STEM cell

HyperBranch Medical raises $1M in new funding

The financing for the Durham-based firm that is backed by The Aurora Funds follows a $2.1 million fundraising nearly a year ago. Six existing investors in the company participated in the latest offering,

Metabolon lands $13.1M in fourth round of venture financing

The Triangle-based company, which focuses on biomarker technology, secures a new investor. Local venture firm Aurora Funds also is an investor.

Metabolon’s “Analytical Platform”:

Argos Therapeutics files for $86M initial public offering

The Durham-based biopharmaceutical firm focuses on individualized therapies targeting cancer, HIV and infectious diseases. Its investors include Intersouth Partners and Aurora Funds.

Argos process

Stem cell-focused Aldagen raises $1.1M in funding

The Durham-based company recently withdrew plans for an $80 million stock offering.

A purified STEM cell

Durham-based Regado Biosciences closes on $26M in new financing

The company, which raised $23 million in 2007, has been working on its new round since 2009. Regado is developing a DNA-based system to control bleeding.

Chemical tech firm Centice raises $2.3M in new funding

The Morrisville-based company, which reorganized its management in 2009, says the funds will be used to drive growth of existing, new chemical verification and identification products.

Cetnice's PASS Rx

Roll this: Video tech firm Digitalsmiths raises $12.5M

The Durham-based startup sometimes touted as the "Google of video" is growing face, developing more technology that's finding increasing demand in the online video archiving space.

Clip from "Top Gun" as tagged by Digitalsmiths

Stem cell firm Aldagen withdraws planned $80.5M IPO

The Durham-based life science company cites "market conditions" as the reason for the pullback. It's the second time that the company, which is backed by Triangle venture firms Intersouth and Aurora, has cancelled an IPO.

A purified stem cell

Holden Thorp emphasizes entrepreneurial thinking to Triangle execs

In presentation to Triangle's Association for Corporate Growth chapter, the UNC-CH chancellor and entrepreneur touts the power of universities in sparking creativity and growth. But he also says work remains to be done to help create a more prosperous future.

Venture-backed HyperBranch raises $2M in new funding

The Durham-based medical technology firm secures equity financing from seven investors.